Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Tingting Xu
Observed name:
Xu, Tingting
Institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Fudan University Shanghai Cancer Center,
Shanghai Clinical Research Center
Observed institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Fudan University Shanghai Cancer Center,
First Affiliated Hospital of Anhui Medical University,
Shanghai Clinical Research Center,
Tongji Hospital,
Huazhong University of Science and Technology
show all 7
ORCID:
0000-0003-4643-9441
Observed ORCID:
0000-0003-4643-9441
OpenAlex ID:
A5015617965
Comparison of different risk stratifications for gastric cancer and establishing a simplified risk‐scoring model based on the Kyoto classification
2023
·
Pengyue Zhang
, Tingting Xu
, et al.
·
Journal of Gastroenterology and Hepatology
·
7
Ulinastatin treatment mitigates glycocalyx degradation and associated with lower postoperative delirium risk in patients undergoing cardiac surgery: a multicentre observational study
2025
·
Xiao Ran
, Tingting Xu
, et al.
·
Critical Care
·
5
PDF
The impact of induction chemotherapy response to survival outcomes in oropharyngeal cancer.
2022
·
Qixian Zhang
, Xin Zhou
, et al.
·
Journal of Clinical Oncology
·
1
Subsite-specific benefit of induction chemoimmunotherapy in HPV-negative oropharyngeal squamous cell carcinoma
2026
·
Lin Zhu
, Die Zhang
, et al.
·
Frontiers in Oncology
PDF
Phase III randomized trial of tislelizumab plus gemcitabine/capecitabine (GX) versus tislelizumab plus gemcitabine/cisplatin (GP) as first-line therapy for recurrent/metastatic nasopharyngeal carcinoma: A prospective multicenter study (PROGRESS).
2026
·
Dongmei Ji
, Yanan Yang
, et al.
·
Journal of Clinical Oncology
PDF
Induction toripalimab plus chemotherapy followed by selective chemoradiation de-escalation in HPV-positive oropharyngeal cancer: a single-arm, phase 2 trial (IChoice-02)
2026
·
Xueguan Lu
, Xin Zhou
, et al.
·
Radiotherapy and Oncology
Expert consensus on the combination of Anti-EGFR monoclonal antibodies and immune checkpoint inhibitors in the treatment of head and neck squamous cell carcinoma
2025
·
Liqiong Xue
, Tingting Xu
, et al.
·
Cancer Treatment Reviews
PDF
MR radiomics and neoadjuvant chemo-responsiveness with insights into selective treatment de-intensification in HPV-positive oropharyngeal carcinoma.
2024
·
Xueguan Lu
, Xin Zhou
, et al.
·
Journal of Clinical Oncology
PDF
Selective treatment de-intensification with reduced-dose radiation and omitted concurrent chemotherapy guided by response to induction chemotherapy in HPV-associated oropharyngeal squamous cell carcinoma: A single-arm, phase II trial (IChoice-01).
2022
·
Xueguan Lu
, Tingting Xu
, et al.
·
Journal of Clinical Oncology
A Ten-year Experience of the Multidisciplinary Management of the Regional Failure of Nasopharyngeal Carcinoma in the Era of IMRT
2020
·
xiyin Guan
, Xing Xing
, et al.
·
Research Square
PDF
Show more works
View as search
Works count:
14
Citation count:
13
H-index:
2
I10-index:
Year
Topic
Type